Track topics on Twitter Track topics that are important to you
Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies articles that have been published worldwide.
We have published hundreds of Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies news stories on BioPortfolio along with dozens of Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies Clinical Trials and PubMed Articles about Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies Companies in our database. You can also find out about relevant Treosulfan-based Conditioning For Allogeneic Stem-cell Transplantation (SCT) In Lymphoid Malignancies Drugs and Medications on this site too.
Natural killer (NK)/T-cell lymphoid malignancy comprises extra-nodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL), and the outcomes for advanced or relapsed/refractory ENKTL and ANKL remain poor. Allogeneic stem cell transplantation (SCT) can be used as a frontline consolidation treatment to prevent the relapse of advanced disease or as salvage treatment after chemotherapy for relapsed sensitive disease.
Treosulfan, Fludarabine and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: a Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based t...
Salvage chemotherapy induces disease remissions in patients with relapsed or refractory (r/r) T-cell lymphomas, but fails to provide lasting tumor control. We analyzed the outcome after peripheral blood stem and bone marrow transplantation (PBSCT, n = 80; BMT, n = 4) from matched related (MRD, n = 22) or matched and unmatched unrelated donors (MUD and MMD, n = 53 and n = 9, respectively) following conditioning with fludarabine, busulfan, and cyclophosphamide (FBC) for 84 consecutive pati...
For many inborn errors of metabolism (IEM), allogeneic hematopoietic stem cell transplantation (HUSCT) is the only cure.
T - and natural killer (NK) cell neoplasms are a heterogeneous group of rare diseases with often inferior outcome. Only few studies exist, clarifying the role of allogeneic transplantation in different clinical scenarios. Larger prospective randomized studies are largely missing even for the more frequent entities. Mostly retrospective analysis and anecdotal reports of patients with advanced disease are available, hampering direct conclusions on the significance of allogeneic stem cell transplantation (allo...
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Reduced-intensity conditioning (RIC) regimens with low tolerable toxicities have been used for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the relapse rate by this treatment is high. Treatment of CD19 B-cell relapsed/refractory acute lymphoblastic leukemia (r/r ALL) with allogeneic chimeric antigen receptor-modified T (CAR-T) cells is safe and effective. Use of allogeneic CD19-CAR-T cells as a part of RIC regimens for treatment of r/r ALL patients with haploidentical HSCT has no...
Graft-versus-host disease-free, relapse-free survival (GRFS) is a composite endpoint that measures survival free of relapse or significant morbidity following allogeneic hematopoietic stem cell transplantation (HSCT). Consecutive 324 adult patients who received HSCT with fluarabine and busulfan based conditioning for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia evolved from MDS were retrospectively analyzed. 1-year and 3-year GRFS rates were 47.8% and 34.5%, respectively. Three fixed f...
Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity.
Pre-transplantation serum ferritin (SF) has been considered to be a potential prognostic biomarker in patients undergoing allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), but this conclusion remains controversial. Thus, we performed a meta-analysis to investigate the prognostic significance of pre-transplantation SF in patients undergoing allogeneic HSCT.
Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients undergone allo-HSCT, which was the largest population-based cohort report...
The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging.
Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown.
Graft versus host disease (GVHD) is a recognized complication of allogeneic stem cell transplantation (allo-SCT) and may affect muscle. We investigated the incidence and subtypes of inflammatory myopathy (IM) in South Australian recipients of allo-SCT.
Fludarabine with busulfan (FB) or melphalan (FM) are two more commonly used reduced intensity conditioning regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these two RIC regimens. We searched electronic databases from inception through November 1, 2017 for literature search to identify relevant studies. DerSimonian random effects model was used to measure efficacy outcomes; hazard ratios and corresponding 95% confidence interval ar...
Outcomes for patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years.
Melphalan-Based Reduced Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (AlloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study, we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent AlloHCT with melphalan (Mel)-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was pro...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment for high risk hematological malignancies in pediatric population, but relapse remains the leading cause of death. We analyze risk factors associated with relapse.
Current standard of care for patients with Hodgkin's and non-Hodgkin's lymphoma is high does conditioning with autologous stem cell transplantation (ASCT). For some patients (i.e., highest risk disease, insufficient stem cell number after mobilization, or patients whose bone marrow is involved with the disease) allogeneic transplantation (alloHCT) offers potential cure. However, majority of patients undergoing alloHCT, receive reduced intensity conditioning as preparative regimen and studies assessing outco...
Hemorrhagic cystitis (HC) is usually a serious complication in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. In this study, our aim is to define risk factors and outcomes for patients with HC in allo-HSCT setting.
Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
A conditioning regimen with fludarabine and myeloablative dose of busulfan (FLU/BU4) has been commonly used in allogeneic hematopoietic cell transplantation (allo-HCT). However, there are two major problems with this regimen: insufficient anti-leukemic effect, especially in advanced cases, and slow time to complete donor-type chimerism, especially T-cell chimerism. To overcome these issues, we designed a combination regimen with FLU (150 mg/m), intravenous BU (12.8 mg/kg), and melphalan (100 mg/m) (FLU/B...
Carmustine (BCNU)-Etoposide-Citarabine-Melphalan (BEAM) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to Fotemustine-substituted BEAM (FEAM), lacking proof of equivalence.
Biomarkers measured in blood chemistry before allogeneic hematopoietic stem cell transplantation (HSCT) may reflect patients' physiological status. We hypothesized that selected markers are predictive for non-relapse mortality (NRM) following transplantation and could contribute to risk assessment.
We read with interest the recent paper by Molina and coworkers, who studied the relationship between anti-Pneumocystis prophylaxis and Nocardia infections in allogeneic hematopoietic stem cell transplant recipients. The authors concluded that the use of atovaquone may be associated with an increased risk of Nocardia infection after allogeneic hematopoietic stem cell transplantation, as compared with cotrimoxazole. In response, we would like to make three comments.